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plantation, Krishnamurthy et al. [1] report very favorable
clinical outcomes after preemptive donor lymphocyte infu-
sion (pDLI) or therapeutic donor lymphocyte infusion (tDLI)
in patients with low levels of donor chimerism or relapsed
disease, respectively, after allogeneic hematopoietic stem
cell transplantation (HSCT). Patients were conditioned with
regimens containing alemtuzumab or antithymocyte glob-
ulin, producing in vivo T cell depletion (TCD). Thirty-two of
62 patients (52%) received pDLI within 6 months, and these
patients had a 5-year overall survival of 80% and an event-
free survival of 65%. Fifty-one patients with relapsed or
persistent disease who received tDLI had a 5-year overall
survival of 40%. Survival was better in patients who received
tDLI at more than 6 months after HSCT compared with those
who did so at less than 6 months after HSCT.
The surprising results from this study, inwhichmore than
half of the patients received pDLI within 6 months after
undergoing HSCT, are the relatively low incidence of graft-
versus-host disease (GVHD; 31% after pDLI versus 45% after
tDLI) and the low rate of GVHD-related deaths (3% after pDLI
versus 2% after tDLI). Furthermore, only 7 deaths (11%) due to
disease relapse occurred in the patients who received pDLI,
despite the low number of donor T cells in the DLI (median
dose, 1.5  106 donor T cells/kg).
In contrast to Krishnamurthy et al., Liga et al. [2] recently
reported severe GVHD in 47% of pDLI recipients treated for
high-risk disease or for mixed chimerism after HSCT with an
alemtuzumab-containing conditioning regimen. In that
series, GVHD was the major factor in death in 27% of the
patients who received DLI.
In the more than 50 years since the ﬁrst HSCT, there have
been signiﬁcant improvements in care, with various strate-
gies to overcome treatment-related mortality; nonetheless,
enhancing the graft-versus-tumor (GVT) reaction without
increasing GVHD remains the greatest challenge in the ﬁeld.
Using a preclinical murine model and in a phase 1 clinical
trial, we have shown that DLI consisting of allogeneic T cells
treated with low-dose irradiation preserved GVT effects
without increased GVHD, owing to retention of short-term
cytotoxicity without the potential for clonal expansion of
irradiated T cells [3].Financial disclosure: See Acknowledgments on page 508.
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http://dx.doi.org/10.1016/j.bbmt.2013.02.005The use of regulatory T (Treg) cells in DLI may reduce the
risk of GVHD fromconventional T (Tcon) cells. For example, in
one study, 28 patients treated with CD34-selected,
haploidentical, HLA-mismatched grafts received ex vivo
CD4þCD25þ Treg cells, followed by Tcon infusion on day 0 [4].
Surprisingly, only 8% of patients developed GVHD, and 92% of
patients achieved remission,with an overall survival of 46% at
1 year [4]. Other strategies for limiting the potential for DLI to
cause GVHD while retaining GVT activity include the
sequential administration of graded doses of donor lympho-
cytes [5], the use of high-dose cyclophosphamide as phar-
macologic GVHDprophylaxis after DLI in haploidentical HSCT
[6] and the administration of DLI depleted of CD8 Tcells [7-9].
Interpreting thesedifferentDLI strategies andchoosing the
optimum approach for each individual patient is confounded
by factors that strongly inﬂuence whether the infusion of
additionaldonorTcellswill causeGVHD.These factors include
(1) intensityof the conditioning regimen, (2)useof invivoTCD
(alemtuzumab or antithymocyte globulin serotherapy) or
ex vivo TCD (CD34þ selection and/or TCD), (3) timing of DLI
afterallo-HSCT, (4) Tcell dose andTcell subsets in theDLI (CD4
versus CD8 T cells), (5) degree of donorerecipient HLA
mismatch, (6) type and amount of residual cancer (eg, acute
myelogenous leukemia, acute lymphocytic leukemia, chronic
myelogenous leukemia, ormultiplemyeloma), (7) intensity of
posttransplantation immunosuppression, and (8) level of
donor chimerism at the time of DLI.
The appropriate use of pDLI and tDLI in the setting of
in vivo TCD and reduced-intensity conditioning must be
informed by an understanding of how these factors impact
the observed incidence and severity of GVHD. Figure 1
describes the interaction of some of the effects of the time
from initial transplant to DLI, T cell dose, TCD, and HLA
mismatch on the degree of GVHD that might occur after DLI.
The risk of GVHDafterDLI is classiﬁed as low (<25%),medium
(25%-50%), or high (>50%). In patients who underwent allo-
geneic HSCT with in vivo TCD (as in the study of Krishna-
murthyet al.), DLI therapy is predicted to result inmoreGVHD
for a given T cell dose compared with patients who received
conventional T cellereplete transplantations and less GVHD
compared with patients who received grafts depleted of
donor T cells through ex vivo manipulation [8-12].
The idea that the degree of GVHD caused by DLI varies
according to the level of TCD in the initial transplantation is
based on a wide variation of intrinsic alloreactivity across
different donorerecipient pairs with the same level of HLA
mismatch. In a given population of allograft recipients, those
with high donorerecipient alloreactivity are more likely to
develop acute GVHD posttransplantation and are excluded
from DLI therapy. The intrinsic level of donorerecipient
alloreactivity is lower in the remaining patients without
posttransplantation GVHD, leading to a low incidence of
severe GVHD when DLI is administered for mixed chimerism
or relapsed disease. In contrast, the intrinsic donorerecipient
alloreactivity is untested in patients who do not develop
GVHD after receiving a CD34-selected allograft (containing
Figure 1. Risks of developing GvHD determined by interplay between timing,
T cell doses of DLI, types of TCD, and degree of HLA mismatch. As an example,
data for the timing, cell dose and use of in vivo TCD from the report in pDLI of
Krishnamurthy et al. is shown as an “X” on the ﬁgure.
H.D. Yun, E.K. Waller / Biol Blood Marrow Transplant 19 (2013) 505e508508essentially no T cells). Thus, DLI administered after a T
celledepleted graft is predicted to lead to higher rates of
GVHD compared with DLI administered to recipients of a T
cellereplete graft.
From this perspective, strategies to deﬁne the safe dose of
donor T cells and the optimal time of administration in
deﬁned cohorts of patients treatedwithuniformconditioning
regimens and GVHD prophylaxis are needed. The study by
Krishnamurthy et al. advances our knowledge in this ﬁeld.
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